title: Statin use and risk of hepatocellular carcinoma in a U.S. population.
abstract: OBJECTIVE
  Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are medications widely prescribed to reduce cholesterol levels. Observational studies in high-risk populations, mostly in Asia, have suggested that statins are associated with a reduced risk of hepatocellular carcinoma (HCC). The current study sought to evaluate the association of statin use and HCC in a U.S.-based, low-risk, general population.
  
  
  METHODS
  A nested case-control study was conducted among members of the Health Alliance Plan HMO of the Henry Ford Health System enrolled between 1999 and 2010. Electronic pharmacy records of statin use were compared among tumor registry-confirmed cases of HCC (n=94) and controls (n=468) matched on age, sex, diagnosis date, and length of HMO enrolment.
  
  
  RESULTS
  In multivariate analyses, ever-use of statins was significantly inversely associated with development of HCC (Odds ratio (OR): 0.32, 95%CI: 0.15-0.67). No clear dose-response relationship was evident as statin use for <2 years (OR=0.32, 95%CI=0.13-0.83) and >2 years (OR=0.31, 95CI%=0.12-9.81) resulted in very similar ORs.
  
  
  CONCLUSIONS
  The use of statins among populations in low-risk HCC areas may be associated with decreased risk of HCC.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: mcglynnk@mail.nih.gov.
authors.forename: Katherine A
authors.initials: KA
authors.lastname: McGlynn
authors.affiliation: Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI, United States.
authors.forename: George W
authors.initials: GW
authors.lastname: Divine
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
authors.forename: Vikrant V
authors.initials: VV
authors.lastname: Sahasrabuddhe
authors.affiliation: Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States.
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Engel
authors.affiliation: Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI, United States.
authors.forename: Ashley
authors.initials: A
authors.lastname: VanSlooten
authors.affiliation: Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI, United States.
authors.forename: Karen
authors.initials: K
authors.lastname: Wells
authors.affiliation: Boston University, Boston, MA, United States.
authors.forename: Marianne Ulcickas
authors.initials: MU
authors.lastname: Yood
authors.affiliation: Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI, United States.
authors.forename: Sharon Hensley
authors.initials: SH
authors.lastname: Alford
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000517:prevention & control*; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012306:Risk; D013997:Time Factors; D014481:United States / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Epidemiology; Liver cancer; Statins
references.citation: Eur J Cancer Prev. 2013 May;22(3):229-34
references.pmid: 23010949
references.citation: Oncogene. 2012 Nov 29;31(48):4967-78
references.pmid: 22310279
references.citation: Lancet. 2010 Dec 4;376(9756):1916-22
references.pmid: 21109302
references.citation: Nat Rev Cancer. 2005 Dec;5(12):930-42
references.pmid: 16341084
references.citation: J Clin Oncol. 2013 Apr 20;31(12):1514-21
references.pmid: 23509319
references.citation: J Am Coll Cardiol. 2011 Jul 26;58(5):530-7
references.pmid: 21777752
references.citation: N Engl J Med. 2005 May 26;352(21):2238-9
references.pmid: 15917390
references.citation: Am J Gastroenterol. 2013 Aug;108(8):1314-21
references.pmid: 23752878
references.citation: Curr Cancer Drug Targets. 2005 Dec;5(8):579-94
references.pmid: 16375664
references.citation: Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36
references.pmid: 17944002
references.citation: Eur J Epidemiol. 2013 Jun;28(6):485-92
references.pmid: 23681775
references.citation: Am J Gastroenterol. 2011 May;106(5):894-8
references.pmid: 21157439
references.citation: J Clin Oncol. 2012 Feb 20;30(6):623-30
references.pmid: 22271485
references.citation: J Hepatol. 2012 Feb;56(2):305-7
references.pmid: 21963520
references.citation: J Virol. 2011 Dec;85(24):13373-83
references.pmid: 21994451
references.citation: Clin Liver Dis. 2011 May;15(2):223-43, vii-x
references.pmid: 21689610
references.citation: PLoS One. 2012;7(1):e29849
references.pmid: 22276132
references.citation: Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):196-202
references.pmid: 19856484
references.citation: Int J Cancer. 2005 Apr 20;114(4):643-7
references.pmid: 15578694
references.citation: Am J Cardiol. 2006 Apr 17;97(8A):77C-81C
references.pmid: 16581333
references.citation: Chem Res Toxicol. 2014 Jan 21;27(1):3-6
references.pmid: 24215631
references.citation: J Epidemiol. 2006 Sep;16(5):201-6
references.pmid: 16951539
references.citation: Gut. 2013 Jun;62(6):951-2
references.pmid: 23263525
references.citation: J Natl Cancer Inst. 2012 Dec 5;104(23):1808-14
references.pmid: 23197492
references.citation: Gastroenterology. 2013 Feb;144(2):323-332
references.pmid: 23063971
references.citation: Clin Cancer Res. 2003 Jan;9(1):10-9
references.pmid: 12538446
references.citation: Am J Gastroenterol. 2008 Jun;103(6):1383-9
references.pmid: 18410471
references.citation: Expert Opin Drug Saf. 2013 Jan;12(1):19-27
references.pmid: 23199231
references.citation: Lancet. 2010 Nov 13;376(9753):1670-81
references.pmid: 21067804
references.citation: Gastroenterology. 2009 May;136(5):1601-8
references.pmid: 19208359